Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06624371
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-01
Brief Title:
Atovaquone Combined with Radiation in Children with Malignant Brain Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Atovaquone Combined with Radiation in Children with Malignant Brain Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AflacBT2303
Brief Summary:
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy RT for the treatment of pediatric patients with newly diagnosed pediatric high-grade gliomadiffuse midline gliomadiffuse intrinsic pontine glioma pHGGDMGDIPG
The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGGDMGDIPG and medulloblastoma MB or pHGGDMGDIPG after completion of RT and before progression
The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGGDMGDIPG and medulloblastoma MB or pHGGDMGDIPG after completion of RT and before progression
Detailed Description:
Atovaquone an FDA-approved antiparasitic drug is being explored as a potential treatment for certain cancers particularly leukemia and pediatric brain tumors like high-grade gliomas Since Atovaquones safety and dosage are already established repurposing it for cancer treatment is cost-effective
Research shows that Atovaquone can inhibit a protein called STAT3 which is involved in cancer cell survival and immune response suppression By doing this it may enhance the effectiveness of radiation therapy especially in tumors with low oxygen levels In animal studies and early clinical trials Atovaquone has shown promise in reducing tumor size and improving survival rates
For pediatric brain tumors which often resist standard treatments Atovaquones ability to cross the blood-brain barrier could make it particularly valuable Ongoing clinical trials are examining its effects in combination with radiation therapy for treating newly diagnosed high-grade gliomas and relapsed medulloblastomas Overall Atovaquones repurposing could lead to new effective treatment options for difficult-to-treat cancers in children
Research shows that Atovaquone can inhibit a protein called STAT3 which is involved in cancer cell survival and immune response suppression By doing this it may enhance the effectiveness of radiation therapy especially in tumors with low oxygen levels In animal studies and early clinical trials Atovaquone has shown promise in reducing tumor size and improving survival rates
For pediatric brain tumors which often resist standard treatments Atovaquones ability to cross the blood-brain barrier could make it particularly valuable Ongoing clinical trials are examining its effects in combination with radiation therapy for treating newly diagnosed high-grade gliomas and relapsed medulloblastomas Overall Atovaquones repurposing could lead to new effective treatment options for difficult-to-treat cancers in children
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None